Hongjin Lai
Yi Liu
Juan Wu3†
Senyi Deng- 1Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China
- 2West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
- 3Department of Outpatient, West China Hospital, Sichuan University, Chengdu, China
Inflammatory processes are essential for innate immunity and contribute to carcinogenesis in various malignancies, such as colorectal cancer, esophageal cancer and lung cancer. Pharmacotherapies targeting inflammation have the potential to reduce the risk of carcinogenesis and improve therapeutic efficacy of existing anti-cancer treatment. Non-steroidal anti-inflammatory drugs (NSAIDs), comprising a variety of structurally different chemicals that can inhibit cyclooxygenase (COX) enzymes and other COX-independent pathways, are originally used to treat inflammatory diseases, but their preventive and therapeutic potential for cancers have also attracted researchers’ attention. Pharmacogenomic variability, including distinct genetic characteristics among different patients, can significantly affect pharmacokinetics and effectiveness of NSAIDs, which might determine the preventive or therapeutic success for cancer patients. Hence, a more comprehensive understanding in pharmacogenomic characteristics of NSAIDs and cancer-related inflammation would provide new insights into this appealing strategy. In this review, the up-to-date advances in clinical and experimental researches targeting cancer-related inflammation with NSAIDs are presented, and the potential of pharmacogenomics are discussed as well.
Introduction
As a fundamental innate immune response, inflammation is involved in tissue repair, defending against pathogens and other danger signals. Transient and well-organized inflammation is salutary while chronic inflammation has been proved to be related to the development of different malignancies (Grivennikov et al., 2010; Elinav et al., 2013; Greten and Grivennikov, 2019). Chronic inflammation can be evoked by both infectious and non-infectious processes of chronic injury or irritation, especially in organs exposed to the external environment (Ulrich et al., 2006). Besides, cancer-intrinsic and therapy-induced metabolic changes, cell stress and cell death are also important sources of cancer-associated inflammation (Hou et al., 2021). Chronic inflammation is regarded as an aberrantly prolonged immune response which results in epigenetic alterations that drive cancer initiation and progression, as well as the accumulation of growth factors that support the development of nascent cancer (Hou et al., 2021). Continuous production of various inflammatory molecules (cytokines, chemokines, prostaglandins, etc.) and recruitment of inflammatory cells within the tumor microenvironment (TME) promote tumor progression, metastasis and even therapy resistance (Greten and Grivennikov, 2019; Wang D. et al., 2021; Hou et al., 2021).
Preclinical and epidemiological evidences suggest that agents with anti-inflammatory effect, such as non-steroidal anti-inflammatory drugs (NSAIDs), have the potential to prevent or delay cancer initiation and improve therapeutic efficacy of cytotoxic agents, targeted agents and immune checkpoint inhibitors (Crusz and Balkwill, 2015). NSAIDs comprise a group of structurally diverse chemicals that can reduce the synthesis of prostaglandins by inhibiting the activity of the cyclooxygenase (COX) enzymes and other COX-independent pathways. The expression level of COX-2, an inducible isoform of the COX enzyme family, has been found elevated in breast cancer, prostate cancer, pancreatic cancer, lung cancer, bladder cancer and so on (Hashemi Goradel et al., 2019). Aspirin, one of the most classical NSAIDs, has been proved to be associated with decreased incidence and mortality of colorectal cancer (Li et al., 2015; Wang L. et al., 2021). Defined as pharmacological intervention to prevent or delay the process of carcinogenesis, cancer chemoprevention is now considered a practicable approach, especially with NSAIDs. In patients diagnosed with malignancies, concurrent use of NSAIDs with cytotoxic agents, targeted agents or immune checkpoint inhibitors seems to be hopeful as well (Edelman et al., 2008; Cortellini et al., 2020; Liu et al., 2020).
Despite the promising anti-cancer effects of NSAIDs, their treatment response varies among patients for many reasons, particularly because of inter-individual genetic differences of specific genes that are involved in drug metabolism or drug-induced signal transduction, and certain genetic variations have a significant impact on pharmacokinetics and effectiveness of specific drugs (Ulrich et al., 2006). Accordingly, the study of variations of genetic characteristics related to drug response is defined as pharmacogenomics (Roden et al., 2019). For instance, carriers of specific NF-κB variants might benefit from NSAIDs in cancer chemoprevention (Chang et al., 2009; Seufert et al., 2013). Therefore, taking account of relevant pharmacogenomic differences makes it possible to enhance the chemopreventive and therapeutic potential of NSAIDs in the treatment of malignancies.
In this article, we summarized general concept of inflammation and cancer development, and then highlighted advances in NSAID-targeted pro-cancer mechanisms involved in this process. The distinct results of clinical studies in chemoprevention and treatment of cancer with NSAIDs were presented and discussed as well. Furthermore, NSAID metabolism and its anti-cancer mechanisms, as well as related pharmacogenomic characteristics, were demonstrated. Factors affecting the effectiveness or risk of NSAIDs other than pharmacogenomic features were also mentioned.
Inflammation and cancer development
Inflammation is a defensive response against infection and tissue injury, which can constrain the spread of pathogens or facilitate tissue repair. In the initiation of inflammation, pathogen-associated molecular patterns (PAMPs) expressed by pathogens or damage-associated molecular patterns (DAMPs) produced in sterile tissue injury or infection-related cell damage can be recognized by pattern recognition receptors (PRRs), which are generally expressed by innate immune cells, such as mast cells, tissue macrophages and dendritic cells (Zhao et al., 2021). Then these innate immune cells activate signal transduction pathways that promote the antimicrobial or proinflammatory functions, including secreting proinflammatory cytokines, chemokines and vasoactive amines (Zindel and Kubes, 2020). As a consequence, leukocytes and plasma proteins involved in innate immunity are recruited to sites of infection or tissue injury, where they start to eliminate microbes or cell debris and repair damaged tissue in a well-orchestrated way (Zindel and Kubes, 2020). Actually, when inflammatory cell recruitment reaches its peak, it is typically followed by clearance of these cells and the restoration of tissue homeostasis, and this process is known as resolution (Fullerton and Gilroy, 2016). However, if the proinflammatory stimulus is not eliminated during the acute phase of inflammation within several days or weeks, it will lead to incomplete or frustrated resolution and then develop into chronic inflammation, which has been proved to be associated with an increased risk for cancer (Grivennikov et al., 2010; Fullerton and Gilroy, 2016; Zhao et al., 2021).
During acute and chronic inflammation, the expression levels of proinflammatory molecules are upregulated, such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α and interferon (IFN) γ, which are able to induce the synthesis of various eicosanoids, including prostaglandins (Aoki and Narumiya, 2012; Wang B. et al., 2021). Prostaglandins (PGs, including PGD2, PGE2, PGF2α, PGI2 and thromboxane A2) are synthesized from arachidonic acid by cyclooxygenase (COX), whose Human Genome Organization name is prostaglandin-endoperoxide synthase (Aoki and Narumiya, 2012; Wang D. et al., 2021). There are two COX isoforms: COX-1 (PTGS1) and COX-2 (PTGS1). COX-1 is constitutively expressed in most tissues, where it plays a role in maintaining tissue homeostasis by providing basal levels of prostaglandins (Wang B. et al., 2021). By contrast, COX-2 usually has limited expression in normal tissues, but it is highly inducible in response to IL-1β, TNFα and IFNγ, especially at sites of inflammation and during tumor progression (Hashemi Goradel et al., 2019). Both COX isoforms can transform arachidonic acid into prostaglandin G2 (PGG2) and, subsequently, into PGH2, which is finally converted into various prostaglandins via specific synthases (Figure 1). Prostaglandins then exert their actions by activating G-protein-coupled receptors on the cell surface, including the PGD2 receptors (DP1 and DP2), the PGE2 receptors (EP1, EP2, EP3, and EP4), the PGF2α receptor (FP), the PGI2 receptor (IP) and the thromboxane A2 receptor (TP) (Funk, 2001). In some cases, nuclear receptors such as peroxisome proliferator-activated receptors (PPARs) can also be activated by certain prostaglandins or their metabolites (Wang and Dubois, 2010).
FIGURE 1. Synthetic and signal transduction pathways of prostaglandins. Arachidonic acid can be transformed into PGG2 and PGH2 via COX enzymes, which can be inhibited by NSAIDs. Then PGH2 is converted into various prostaglandins via specific synthases. Prostaglandins then exert their actions by activating receptors on cell membranes, including DP1-2, EP1-4, FP, IP and TP. Nuclear receptors such as PPARγ and PPARδ can also be activated by prostaglandins or their metabolites. Abbreviations: PGG2, prostaglandin G2; PGH2, prostaglandin H2; PGDS, PGD synthase; PGES, PGE synthase; PGFS, PGF synthase; PGIS, PGI synthase; TBXAS1, TXA synthase; peroxisome proliferator-activated receptor (PPAR).
Constant exposure to proinflammatory stimulus, whether it is infectious or non-infectious, is responsible for the overexpression of COX-2 and development of chronic inflammation, which might lead to malignancies, such as hepatitis virus infection-related hepatocellular carcinoma (Lu et al., 2015), reflux esophagitis-related esophageal cancer (Yang et al., 2012) and inflammatory bowel disease-related (IBD) colorectal cancer (Ullman and Itzkowitz, 2011). Previous research demonstrated that COX-2 achieved cancer-promoting effects mainly by its downstream prostaglandins, which contributed to cancer initiation, progression and resistance to treatment (Hashemi Goradel et al., 2019; Hou et al., 2021). COX-2 can be expressed by cancer cells, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs) and regulatory T (Treg) cells (Hashemi Goradel et al., 2019). The upregulated expression of COX-2 has been observed in numerous premalignant and malignant diseases, including colorectal adenoma, Barrett’s esophagus, colorectal cancer, gastric cancer, esophageal cancer, breast cancer, lung cancer, glioblastoma and so on (Wang and Dubois, 2006; Jiang et al., 2017; Wang D. et al., 2021). It is generally accepted that COX-2 contributes to carcinogenesis mainly via overproducing prostaglandins, especially PGE2.
Besides COX enzymes, NSAIDs exert their function through COX-independent pathways as well. Several mechanisms have been proposed to demonstrate the tumor-promoting effects of NSAID-targeted signals, which are summarized as follows (Figure 2). Overproduction of PGE2 in tumor tissues usually results in resistance to apoptosis of cancer cell, as well as enhanced ability in proliferation, migration and invasion (Wang and Dubois, 2010; Lee et al., 2019; Cui et al., 2021). Besides, PGE2 promotes angiogenesis in cancer development (Zhang and Daaka, 2011; Xu et al., 2014). Generation of immunosuppressive tumor microenvironment (TME) by regulating tumor-infiltrating immune cells is also achieved by PGE2, which includes stimulating type-2 macrophage polarization, inducing T cell dysfunction and preventing tumor infiltration of dendritic cells or cytotoxic T lymphocytes (Ahmadi et al., 2008; Liu et al., 2012; Sun et al., 2022). The emergence of cancer stem cells (CSCs) is related to different PGE2-related signaling pathways as well (Li et al., 2012; Wang et al., 2015; Fang et al., 2017). Aspirin could promote apoptosis in CSCs in a COX-independent pathway (Chen et al., 2018). In addition, epigenetic regulation such as DNA methylation of tumor suppressive genes induced by PGE2 promotes cancer development (Xia et al., 2012; Wong et al., 2019). Except for PGE2, thromboxane A2, another COX-2 derived production, was reported to be related to enhanced tumor angiogenesis (Pradono et al., 2002). Whereas abundant evidences suggested contribution of COX-2 in various cancers, the role for COX-1 in cancer development remains much less discovered. Several studies showed that COX-1-dependent pathways was required for carcinogenesis, tumor growth and metastasis in certain malignancies as well (Daikoku et al., 2005; Li et al., 2014; Lucotti et al., 2019).
FIGURE 2. Tumor-promoting inflammation-related signals that can be targeted by NSAIDs. Both infectious and non-infectious chronic inflammation contributes to carcinogenesis via increasing PGs and activating COX-independent signals that can be suppressed by NSAIDs. These COX-dependent and independent pathways promote cancer development by inducing resistance to PCD, and facilitating proliferation, migration and invasion. Induction of tumor angiogenesis, immunosuppressive TME and other mechanisms are also achieved by NSAID-targeted signals. Abbreviations: HBV, hepatitis B virus; IBD, inflammatory bowel disease; PGs, prostaglandins; PCD, programmed cell death; TME, tumor microenvironment.
Clinical outcomes of non-steroidal anti-inflammatory drugs in treating cancer-related inflammation
NSAIDs constitute a group of drugs with diverse chemical structure, which share a common mechanism of action by inhibiting COX activity and COX-independent pathways. Generally, all NSAIDs compete with arachidonate for the COX active site, which results in decreased production of prostaglandins. Now that COX enzymes and prostaglandins have been proved to be significantly related to cancer development, the application of NSAIDs becomes a promising strategy for the treatment of inflammation-driven cancers. The most commonly used NSAIDs and their clinical trials in chemoprevention or post-diagnosis use are listed in Table 1, and participants in chemoprevention trials were mostly with higher cancer risks.
TABLE 1. Classification, selectivity and anti-cancer clinical trials of classical NSAIDs.
Chemoprevention strategies with NSAIDs have the potential to reduce incidence of several malignancies. Aspirin, one of the most widely used NSAIDs, has been identified as an effective cancer-preventive agent according to numerous epidemiological and clinical studies (Hou et al., 2021). A meta-analysis of 42 observational studies (99,769 cases) suggested an association between aspirin use and reduced incidence of breast cancer (Ma S. et al., 2021). Another meta-analysis based on individual-level data from nine cohort studies (2,600 cases) and 8 case-control studies (5,726 cases) identified a lower ovarian cancer risk associated with frequent aspirin use (Hurwitz et al., 2022). Likewise, the frequency of aspirin use was also emphasized by a meta-analysis in endometrial cancer (7 case-control and 11 cohort studies included, 14,766 cases in total), where the reduced cancer risk was closely related to the high-frequency of aspirin use instead of the duration of use (Wang et al., 2020). In addition to the frequency and duration of aspirin use, dose-effect relationship is a critical issue as well. A meta-analysis focusing on dose-effect relationship between aspirin and cancer risk revealed that high frequency or high dose use of aspirin might increase lung and prostate cancer risks, while low-dose of aspirin use could prevent colorectal cancer (Wang L. et al., 2021). Contrarily, a meta-analysis in hepatocellular carcinoma (HCC) (2 case-control and 16 cohort studies included) showed that the use of aspirin was associated with a lower risk of liver cancer, but not in a dose-dependent or a duration-dependent relationship (Wang et al., 2022). Interestingly, the meta-analysis in HCC concluded that aspirin had protective effects against HCC in patients with hepatitis B virus or hepatitis C virus infection (Wang et al., 2022), which was also supported by a nationwide study of patients with chronic viral hepatitis in Sweden (Simon et al., 2020). Moreover, according to a systematic review and meta-analysis of all observational studies on aspirin use and digestive-tract cancers up to March 2019, aspirin use was related to lower risks in various digestive malignancies, including colorectal cancer (45 studies), squamous-cell esophageal cancer (13 studies), adenocarcinoma of the esophagus and gastric cardia (10 studies), stomach cancer (14 studies), hepatobiliary cancer (5 studies) and pancreatic cancer (15 studies) (Bosetti et al., 2020). However, the findings of two large cohort studies didn’t support that aspirin use was associated with reduced pancreatic cancer risk, except in patients with diabetes (Khalaf et al., 2018). Despite the satisfactory chemoprevention effect of aspirin, it is noteworthy that prophylactic use of NSAIDs should be cautious with different populations. A randomized, double-blind, placebo-controlled trial (9,525 cases receiving aspirin and 9,589 cases receiving placebo) reported that older adults taking daily low-dose aspirin (100 mg) led to an increase in all-cause mortality, primarily due to cancer, and the follow-up data of this trial suggested that aspirin might accelerate the progression of cancer in older adults (McNeil et al., 2018; McNeil et al., 2021). COX-2 selective inhibitors like celecoxib and etodolac also have been proved to be efficient in chemoprevention for non-melanoma skin cancers and gastric cancer (Elmets et al., 2010; Yanaoka et al., 2010). Unlike generally accepted conclusion on the benefit of aspirin in preventing colorectal cancer, it is still questionable whether NSAIDs can reduce cancer risks in certain malignancies. For instance, lung cancer, one of the leading causes of cancer-related deaths, was proved to be of little association between its incidence and aspirin use according to different well-designed studies (Oh et al., 2011; Mc Menamin Ú et al., 2015; Loomans-Kropp et al., 2021). In hematologic malignancies, high use (≥4 days/week for ≥4 years) of acetaminophen was associated with increased incidence of myeloid neoplasms and non-Hodgkin’s lymphomas (Walter et al., 2011).
In addition to prophylactic use as chemoprevention strategies, NSAIDs can also improve the survival in patients who are already diagnosed with certain malignancies, which is supported by numerous observational studies and clinical trials. Post-diagnosis regular aspirin use was associated with reduced colorectal cancer-specific and overall mortality, especially in patients with positive PTGS2 (COX-2) expression and mutated PIK3CA tumors, reported by a meta-analysis (Li et al., 2015). Further studies revealed that, among colorectal cancer patients with low tumoral levels of PD- L1, survival benefit from post-diagnosis aspirin use was greater than in others (Domingo et al., 2013; Hamada et al., 2017). Another prospective cohort study of newly diagnosed biliary tract cancer (BTC) found that post-diagnosis aspirin use was associated with decreased BTC-specific mortality of different subtypes (Liao et al., 2021). In a cohort study of prostate cancer, similar results were observed in patients with high-risk cancers (≥T3 and/or Gleason score ≥8), where postdiagnosis daily aspirin use was associated with lower prostate cancer-specific mortality (Jacobs et al., 2014). In patients with esophageal, hepatobiliary and breast cancer, post-diagnosis use of aspirin was associated with increased survival as well (Fraser et al., 2014; Frouws et al., 2017).
Some clinical proofs supported that cancer patients undergoing radiotherapy or chemotherapy may benefit from additional use of NSAIDs. In prostate cancer patients treated with radiotherapy or radical prostatectomy, aspirin use was associated with a reduced risk of prostate cancer-specific mortality, especially in patients with high-risk disease (Choe et al., 2012). In pre-treated metastatic colorectal cancer patients receiving chemotherapy, aspirin improved overall survival significantly (Giampieri et al., 2017). In advanced non-small cell lung cancer (NSCLC) patients with COX-2 expression undergoing chemotherapy, who received celecoxib had better survival than that in non-users, according to a randomized clinical trial (Edelman et al., 2008). Aspirin could also decrease the proangiogenic effects of tamoxifen (a selective endocrine receptor modulator) in breast cancer patients, which suggested that antiplatelet or antiangiogenic therapy might improve the effectiveness of tamoxifen in breast cancer treatment (Holmes et al., 2008). In postmenopausal breast cancer patients treated with aromatase inhibitors, sulindac, a non-selective NSAID, reduced breast density, which is a risk factor for breast cancer, and the results implied that PGE2 inhibition by NSAIDs might be important for breast density change or collagen modulation during breast cancer development (Thompson et al., 2021). However, the benefit of NSAIDs in patients undergoing chemotherapy is not always satisfactory in certain cancer types or populations. In a randomized clinical trial of stage III colon cancer, additional celecoxib to standard adjuvant chemotherapy for 3 years did not significantly improve disease-free survival of the included patients, compared with patients receiving placebo (Meyerhardt et al., 2021). Similar results were reported by a trial in advanced non-small-cell lung cancer, where additional rofecoxib did not prolong the survival of patients receiving standard chemotherapy (Gridelli et al., 2007). In breast cancer patients receiving aromatase inhibitor treatment, short-term (≤18 months) celecoxib or low-dose aspirin use did not improve event-free survival or distant disease-free survival, and low-dose aspirin use even increased all-cause mortality (Strasser-Weippl et al., 2018).
The emergence of targeted therapies and immunotherapies has successfully prolonged overall survival for all kinds of cancer patients, and the use of NSAIDs along with targeted agents or immune checkpoint inhibitors seems promising. A retrospective analysis in epidermal growth factor receptor-mutant (EGFR) NSCLC patients suggested that concurrent aspirin use with osimertinib (EGFR inhibitor) was associated with prolonged progression-free survival (Liu et al., 2020), and a similar result was also reported in NSCLC (Han et al., 2020). In advanced hepatocellular carcinoma patients receiving sorafenib or regorafenib (multi-target tyrosine kinase inhibitors), concomitant use of aspirin improved their survival (Casadei-Gardini et al., 2021). A multicenter retrospective study showed that aspirin use was independently related to an increased objective response rate among 1012 cancer patients (52.2% NSCLC, 26% melanoma, 18.3% renal cell carcinoma and 3.6% others) treated with PD-1/PD-L1 inhibitors (Cortellini et al., 2020), and a meta-analysis reported that concurrent use of low-dose aspirin was associated with better progression-free survival in cancer patients receiving immune checkpoint inhibitors, including NSCLC (Zhang et al., 2021). Nevertheless, some studies revealed that NSAIDs did not benefit certain patients receiving targeted therapy or immunotherapy. In platinum refractory NSCLC patients, the combination of celecoxib and gefitinib (EGFR inhibitor) did not improve the response rate compared with gefitinib alone (Gadgeel et al., 2007). Immunotherapy with antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) usually results in enterocolitis, and melanoma patients with anti-CTLA-4 enterocolitis took NSAIDs more frequently than patients without enterocolitis, which suggested that patients treated with anti-CTLA-4 were supposed to avoid NSAIDs (Marthey et al., 2016). In addition, concurrent use of immune checkpoint inhibitors and aspirin or NSAIDs did not improve disease control or survival in metastatic renal cell carcinoma patients, and use of NSAIDs was even associated with a higher risk of progression and death (Zhang et al., 2022).
Drug metabolism, anti-cancer mechanisms and pharmacogenomics of non-steroidal anti-inflammatory drugs
Pharmacogenomics in non-steroidal anti-inflammatory drug metabolism
The effectiveness of NSAIDs in cancer chemoprevention and post-diagnosis therapies varies in distinct populations and cancer types, primarily due to diverse genetic characteristics among different malignancies and individuals. The genetic variation of specific genes that are involved in drug metabolism or drug-induced signal transduction might affect the success of chemoprevention or treatment with NSAIDs (Scherer et al., 2014; Li et al., 2015). Taking account of such relevant pharmacogenomic differences has the potential to modify chemopreventive and therapeutic effects of NSAIDs.
Most NSAIDs are administered as active drugs, but some of them are prodrugs that require metabolic activation, such as sulindac. Several metabolic pathways are responsible for inactivation and elimination of NSAIDs, including oxidation (cytochrome P450 enzymes, CYP) and glucuronide conjugation (uridine-5′-diphosphate-glucuronosyl transferases, UGTs). The pharmacokinetic properties of NSAIDs vary among different individuals, partly because of their variance in NSAID metabolism-related genes, which affects plasma concentration and half-life of NSAIDs (Theken et al., 2020). CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) is one of the most important enzymes for the oxidation of NSAIDs as well as other CYP enzymes, especially the CYP2C family (Theken et al., 2020). Besides, glucuronidation through UGTs is also an important pathway for NSAIDs clearance. UGT1A1, UGT1A6, UGT1A7, and UGT1A9 contribute most to aspirin glucuronidation, while the most important enzymes involved in non-aspirin NSAID glucuronidation are other members of the UGT family (Ulrich et al., 2006).
CYP2C enzymes and UGTs are highly polymorphic, and genetic variation of these genes plays a role in the inter-individual variability in NSAID elimination and efficacy. More than 60 variant alleles or multiple sub-alleles of CYP2C9 have been found, which can be categorized according to their functional status as follows: normal function (e.g., CYP2C9*1), decreased function (e.g., CYP2C9*2 and *5), and no function (e.g., CYP2C9*3 and *6) (Theken et al., 2020). Previous researches demonstrated that functional polymorphisms of CYP2C9 and UGT1A6 were related to modified effects of NSAIDs in the chemoprevention of colorectal adenoma and cancer (Bigler et al., 2001; Chan et al., 2005; Samowitz et al., 2006; Chan et al., 2009; Yamazaki et al., 2021). In addition, other functionally relevant polymorphisms of UTGs were also associated with modification of NSAID effectiveness on colorectal cancer risk (Angstadt et al., 2014; Scherer et al., 2014). These inspiring findings emphasize the need for further pharmacogenomic researches to identify individuals that might benefit from NSAIDs in cancer chemoprevention.
Anti-cancer mechanisms and pharmacogenomics of non-steroidal anti-inflammatory drugs
According to classical theories, NSAIDs exert their anti-cancer effects mainly based on COX-dependent mechanisms via inhibiting COX-2 activity and prostaglandin production. Nevertheless, emerging evidences presented some novel targets in COX-independent anti-tumor effects, where NSAIDs directly interacted with proteins other than COX enzymes. COX-independent molecular targets are summarized in Table 2. Pharmacogenetic studies have demonstrated that genetic variation is one of the leading causes of variability in drug response. Among different types of genetic variations that affect inter-individual drug response, single nucleotide polymorphisms (SNPs) play a critical role due to their occurrence frequency of >1% in the human population (Gholamian Dehkordi et al., 2021). Because different NSAIDs have various molecular targets, including the most classical COX enzymes and COX-independent molecules, genetic variations in these genes and their closely related upstream or downstream genes can be tremendous. Therefore, identification of certain determining pharmacogenomic features is critical for predicting drug response and select eligible patients to receive NSAIDs along with standard anti-cancer treatment. For instance, aspirin use was associated with reduced rate of colorectal cancer recurrence in patients with PIK3CA-mutant tumors compared with patients with PIK3CA wild-type tumors (Domingo et al., 2013). Therefore, PIK3CA mutations could be regarded as an effective pharmacogenomic feature in predicting aspirin effectiveness in colorectal cancer patients.
TABLE 2. COX-independent molecular targets of NSAIDs.
Accumulating proofs suggested that NSAIDs were capable of suppressing proliferation, migration and invasion in cancer cells and promoting their programmed cell death. Selecting patients with potential benefits based on their pharmacogenomic characteristics was also supported by some evidences. Various NSAIDs suppressed NF-κB-regulated COX-2 expression in a dose-dependent manner and inhibited the proliferation of tumor cells (Takada et al., 2004). Inhibition of NF-κB pathway induced by aspirin suppressed the growth, migration and metastasis of osteosarcoma (Liao et al., 2015). NF-κB polymorphisms had an impact on cancer risks, and carriers of specific NF-κB variants might benefit from NSAIDs in cancer chemoprevention (Chang et al., 2009; Seufert et al., 2013). In addition to NF-κB, mammalian target of rapamycin (mTOR) pathways can be affected by NSAIDs as well. Aspirin suppressed mTORC1 signaling and the PI3K/AKT, MAPK/ERK pathways, and it showed synergetic anti-cancer efficacy in combination with sorafenib in hepatocarcinoma cells (Sun et al., 2017). By inhibiting AKT/mTOR signaling, aspirin also promoted RSL3-induced ferroptosis in PIK3CA-mutant colorectal cancer cells (Chen et al., 2022). In hepatocellular carcinoma, celecoxib acted synergistically with chemotherapeutic drugs in promoting apoptosis, and celecoxib induced COX-2 inhibition in different apoptotic pathways, including stimulating death receptor signaling, activation of caspases and mitochondrial apoptosis pathway (Kern et al., 2006). Combined use of celecoxib and erlotinib (EGFR inhibitor) also suppressed prostaglandin signaling and promoted apoptosis of intestinal tumors in vivo (Buchanan et al., 2007). Aspirin even triggered disruption of the chromosomal architecture of the COX-2 locus in lung cancer cells during radiation treatment and increased the level of apoptosis (Sun et al., 2018). In lymphoma B cells, celecoxib enhanced the apoptotic activity of TRAIL (TNF-related apoptosis-inducing ligand) through COX-2-independent effects via decelerating the cell cycle and inhibiting expression of survival proteins, like Mcl-1 (Gallouet et al., 2014). Similar targets were verified in colon cancer cells, where combined use of aspirin with sorafenib suppressed proliferation by targeting the anti-apoptotic proteins FLIP and Mcl-1 and sensitized cancer cells to TRAIL (Pennarun et al., 2013). Sulindac could also induce apoptosis by binding to retinoid X receptor-alpha rather than COX, which inhibited TNFα induced PI3K/AKT signaling and activated the death receptor-mediated apoptotic pathway (Zhou et al., 2010). The combination of aspirin and osimertinib inhibited AKT/FOXO3a signaling component phosphorylation and increased Bim expression in osimertinib-resistant NSCLC cells and promoted Bim-dependent apoptosis, which decreased tumor growth in vivo (Han et al., 2020).
Inhibition of tumor angiogenesis is also a significant function of NSAIDs. PGE2-EP3 signaling induced tumor metastasis and angiogenesis by upregulation of matrix metalloproteinase-9 (MMP-9), which could be suppressed by NSAIDs (Amano et al., 2009). Another study proved that PGE2 biosynthesis was dependent on COX-1 rather than COX-2 in endothelial cells, which could be blocked by aspirin in vivo (Salvado et al., 2013). Overexpression of COX-2 stimulated the expression of angiogenic-related genes in breast cancer cells isolated from COX-2 transgenic mice, and treatment with celecoxib suppressed tumor growth and micro-vessel density (Chang et al., 2004). Vascular endothelial growth factors (VEGF) have been identified as major mediators of tumor angiogenesis, and aspirin decreased serum level of VEGF and suppressed the pro-angiogenic effects of tamoxifen in breast cancer patients, where interindividual variability was noted by the researchers (Holmes et al., 2008). Genetic variations in VEGF-A and its receptors 1 (FLT1) and 2 (KDR) were proved to be associated with colon cancer survival, and the association could be modified by NSAID use, which indicated that cancer patients with specific SNPs in these genes could benefit more from NSAIDs (Slattery et al., 2014). In patients with cervical intraepithelial neoplasia 3 (CIN 3), serum VEGF levels were helpful to identify patients who may benefit from celecoxib, which provided novel strategies to cervical cancer chemoprevention (Rader et al., 2017). These results implied the existence of undiscovered pharmacogenomic features related to anti-angiogenesis effects of NSAIDs in cancer treatment.
Cancer stem cells (CSCs) play an important role in cancer recurrence, metastasis and resistance to drugs, and NSAIDs can reduce cancer stem cells according to some researches. In colorectal cancer, NSAIDs (indomethacin, sulindac, aspirin and celecoxib) could inhibit the formation of CSCs and reduce chemotherapy-induced CSCs via inhibiting COX-2 and NOTCH/HES1, and activating PPARγ (Moon et al., 2014). Chemotherapeutic drugs could generate CSCs through an NFκB-IL6-dependent inflammatory environment and result in multidrug resistance in breast cancer, but treatment with aspirin was able to disturb the nuclear translocation of NF-κB in CSCs and improve sensitivity to chemotherapy (Saha et al., 2016). Aspirin could eliminate colorectal CSCs in a COX-independent pathway, where aspirin directly interacted with histone acetyltransferase p300, promoted H3K9 acetylation, activated FasL expression, and resulted in apoptosis in CSCs (Chen et al., 2018).
NSAIDs can also affect the epigenetic regulation of certain genetic loci, which results in anti-cancer effects. Aspirin could reduce histone demethylase (KDM6A/B) expression and suppress the expression of inflammation-related stemness genes (especially ICAM3), and inhibit tumor growth and metastasis (Zhang et al., 2020). A population-based study revealed that aspirin users with unmethylated promotor of BRCA1 and global hypermethylation of long interspersed elements-1 (LINE-1) had lower breast cancer-specific mortality (Wang et al., 2019). This study provided important pharmacogenetic evidence, which implied that epigenetic features of specific susceptibility genes should be taken into consideration before NSAID use.
Evidences showed that the regulation of immune cells in TME was achieved by NSAIDs as well. A prospective cohort study showed that regular aspirin use was related to a lower risk of colorectal carcinomas with low concentrations of tumor-infiltrating lymphocytes (TILs), which implied that aspirin contributed to the increased TILs in tumor tissues (Cao et al., 2016). Inhibition of the COX-2/PGE2/EP4 axis increased tumor-infiltrating immune cells in the microenvironment and restored sensitivity of drug-resistant tumor to pembrolizumab (Pi et al., 2022). The risk of developing breast cancer can be increased by radiotherapy for existing malignancies, post-irradiation use of low-dose aspirin for 6 months in mice could prevent the establishment of an immunosuppressive tumor microenvironment, which was characterized by enriched proinflammatory factors and abundant myeloid cells, and aspirin intervention signiflcantly decreased COX-2 and TGFβ intensity in tumors from irradiated hosts (Ma L. et al., 2021).
In addition to the well-known focus on cancer proliferation, programmed cell death, angiogenesis, stemness, epigenetic regulation and immune regulation, other mechanical and clinical researches revealed some promising pharmacogenomic features as well. A large-scale case-control study showed that NSAID use was associated with reduced risk of colorectal cancer, and the association varied according to genetic variation at two SNPs at chromosomes 12 and 15 (Nan et al., 2015). Tumor repopulation is a major cause of radiotherapy failure, and pancreatic cancer repopulation upon radiation was suppressed by aspirin in vitro and in vivo via inhibiting dying tumor cells from releasing exosomes and PGE2, which were critical for the survival and proliferation of tumor repopulation cells (Jiang et al., 2020). This study suggested that pancreatic cancer patients undergoing radiotherapy might benefit from combined use of aspirin. A study proved that tumor sensitivity to radiotherapy was enhanced by four tested NSAIDs (diclofenac, indomethacin, piroxicam and NS-398) via increasing tumor oxygenation, which was primarily mediated by an effect on mitochondrial respiration (Crokart et al., 2005). In lung cancer, aspirin caused disruption of the chromosomal architecture in the COX-2 locus and reduced its production in cell lines, which enhanced radiosensitivity of lung cancer cells (Sun et al., 2018).
Considerable amounts of studies demonstrated the effectiveness of NSAIDs in chemoprevention and post cancer-diagnosis use in certain cancer types, but there is still requirement for more researches in comprehensively clarifying the underlying anti-cancer mechanisms of NSAIDs, as well as exploring more pharmacogenomic features to guide personalized chemoprevention and treatment.
Conclusion and future directions
Chronic inflammation results in upregulation of proinflammatory molecules, recruitment of inflammatory cells, genetic and epigenetic alterations in normal cells, thus initiating carcinogenesis and cancer development. NSAIDs are capable of suppressing various aberrantly activated genes during inflammation and cancer progression, including the most classical COX enzymes and other COX-independent pro-cancer genes. Numerous epidemiological, clinical and mechanical researches revealed the effectiveness of NSAIDs in chemoprevention and post cancer-diagnosis treatment in both solid tumors and hematological malignancies. However, NSAIDs do not benefit every individual with cancer risk, particularly because of their genetic variations in NSAID-related genes. Detecting such pharmacogenomic features among normal people or cancer patients makes it possible to select individuals who might benefit from NSAIDs in chemoprevention or anti-cancer treatment.
Besides pharmacogenomic features, other factors might have an impact on the effectiveness or toxicity of NSAIDs as well. The dose, duration and frequency of NSAID use is a critical issue. An average daily dose of 100 mg of coated aspirin have favorable preventive effects on cancer, and cancer-specific survival benefit is achieved with aspirin doses as low as 80 mg daily (Chia et al., 2012; Lotrionte et al., 2016). The effective dose and frequency of celecoxib in chemoprevention and treatment varied among different populations, and some recommended doses and frequencies are listed as follows: 400 mg daily for preventing recurrence of breast cancer and colorectal adenoma, 600 mg bid for NSCLC patients receiving erlotinib and 16 mg/kg/day for children with colorectal cancer risk (Reckamp et al., 2006; Lynch et al., 2010; Saxena et al., 2020). Researches focusing on relationship between duration and effectiveness of NSAID use remains limited. Consistent aspirin use over 6 years reduced colorectal cancer risk among men (Chan et al., 2008). Aspirin use over 10 years significantly reduced HCC incidence while the use for 5–10 years only achieved marginal reduction (Fujiwara et al., 2019). Pharmacokinetic interaction with other anti-cancer drugs also affected the effectiveness of NSAIDs. Ibuprofen co-administered with pemetrexed suppressed the clearance of pemetrexed and increased its maximum plasma concentration (Sweeney et al., 2006). Coadministration of celecoxib and capecitabine increased celecoxib exposure in patients, which suggested the importance of close monitoring of cancer patients receiving NSAIDs with a narrow therapeutic index (Ramírez et al., 2019). In addition, selective COX-2 inhibitors such as celecoxib have been associated with great risk of adverse cardiovascular effects, and aspirin use was associated with a higher risk of major bleeding in individuals without cardiovascular disease (Zheng and Roddick, 2019; Schjerning et al., 2020). Such NSAID-related adverse events must be considered before use.
Novel technologies such as liquid biopsy and next generation sequencing have enabled the quick and sensitive detection of pharmacogenomic features among cancer patients (Bignucolo et al., 2017). Early detection and real-time monitoring of NSAID-related pharmacogenomic features could help identify individuals with specific genomic characteristics related to NSAID sensitivity and allow precise selection of patients, thus achieving successful personalized chemoprevention and treatment for cancer.
Author contributions
HL, YL, and JW collected the original literature and drafted the manuscript. JC, HJ, YX, and SD revised and edited the draft. YX and SD supervised the work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
COX, cyclooxygenase; NSAID, non-steroidal anti-inflammatory drug; PPAR, peroxisome proliferator-activated receptors; RXRα, retinoid X receptor α; NF-κB, Nuclear factor-kappa B; AP-1, activator protein 1; SP-1, Transcription factor Sp1; AMPK, adenosine monophosphate-activated protein kinase; mTOR, mechanistic target of rapamycin; PDPK-1, 3-phosphoinositide-dependent protein kinase 1; PDE5, phosphodiesterase 5; SERCA, sarcoendoplasmic/reticulum Ca2+ATPase; CSC, cancer stem-like cells.
References
Ahmadi, M., Emery, D. C., and Morgan, D. J. (2008). Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68 (18), 7520–7529. doi:10.1158/0008-5472.Can-08-1060
Amano, H., Ito, Y., Suzuki, T., Kato, S., Matsui, Y., Ogawa, F., et al. (2009). Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci. 100 (12), 2318–2324. doi:10.1111/j.1349-7006.2009.01322.x
Angstadt, A. Y., Hartman, T. J., Lesko, S. M., Muscat, J. E., Zhu, J., Gallagher, C. J., et al. (2014). The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions. Genes Chromosom. Cancer 53 (6), 454–466. doi:10.1002/gcc.22157
Aoki, T., and Narumiya, S. (2012). Prostaglandins and chronic inflammation. Trends Pharmacol. Sci. 33 (6), 304–311. doi:10.1016/j.tips.2012.02.004
Arico, S., Pattingre, S., Bauvy, C., Gane, P., Barbat, A., Codogno, P., et al. (2002). Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277 (31), 27613–27621. doi:10.1074/jbc.M201119200
Babbar, N., Ignatenko, N. A., Casero, R. A., and Gerner, E. W. (2003). Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J. Biol. Chem. 278 (48), 47762–47775. doi:10.1074/jbc.M307265200
Bigler, J., Whitton, J., Lampe, J. W., Fosdick, L., Bostick, R. M., and Potter, J. D. (2001). CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 61 (9), 3566–3569.
Bignucolo, A., De Mattia, E., Cecchin, E., Roncato, R., and Toffoli, G. (2017). Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment. Int. J. Mol. Sci. 18 (7), 1522. doi:10.3390/ijms18071522
Bosetti, C., Santucci, C., Gallus, S., Martinetti, M., and La Vecchia, C. (2020). Aspirin and the risk of colorectal and other digestive tract cancers: An updated meta-analysis through 2019. Ann. Oncol. 31 (5), 558–568. doi:10.1016/j.annonc.2020.02.012
Buchanan, F. G., Holla, V., Katkuri, S., Matta, P., and DuBois, R. N. (2007). Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 67 (19), 9380–9388. doi:10.1158/0008-5472.Can-07-0710
Cao, Y., Nishihara, R., Qian, Z. R., Song, M., Mima, K., Inamura, K., et al. (2016). Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 151 (5), 879–892. e874. doi:10.1053/j.gastro.2016.07.030
Casadei-Gardini, A., Rovesti, G., Dadduzio, V., Vivaldi, C., Lai, E., Lonardi, S., et al. (2021). Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. HPB Oxf. 23 (6), 915–920. doi:10.1016/j.hpb.2020.09.024
Chan, A. T., Giovannucci, E. L., Meyerhardt, J. A., Schernhammer, E. S., Wu, K., and Fuchs, C. S. (2008). Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134 (1), 21–28. doi:10.1053/j.gastro.2007.09.035
Chan, A. T., Tranah, G. J., Giovannucci, E. L., Hunter, D. J., and Fuchs, C. S. (2005). Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J. Natl. Cancer Inst. 97 (6), 457–460. doi:10.1093/jnci/dji066
Chan, A. T., Zauber, A. G., Hsu, M., Breazna, A., Hunter, D. J., Rosenstein, R. B., et al. (2009). Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136 (7), 21272127–21272136. doi:10.1053/j.gastro.2009.02.045
Chang, E. T., Birmann, B. M., Kasperzyk, J. L., Conti, D. V., Kraft, P., Ambinder, R. F., et al. (2009). Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev. 18 (3), 976–986. doi:10.1158/1055-9965.Epi-08-1130
Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101 (2), 591–596. doi:10.1073/pnas.2535911100
Chen, H., Qi, Q., Wu, N., Wang, Y., Feng, Q., Jin, R., et al. (2022). Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutatnt colorectal cancer. Redox Biol. 55, 102426. doi:10.1016/j.redox.2022.102426
Chen, Z., Li, W., Qiu, F., Huang, Q., Jiang, Z., Ye, J., et al. (2018). Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer. Theranostics 8 (16), 4447–4461. doi:10.7150/thno.24284
Chia, W. K., Ali, R., and Toh, H. C. (2012). Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat. Rev. Clin. Oncol. 9 (10), 561–570. doi:10.1038/nrclinonc.2012.137
Choe, K. S., Cowan, J. E., Chan, J. M., Carroll, P. R., D'Amico, A. V., and Liauw, S. L. (2012). Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 30 (28), 3540–3544. doi:10.1200/jco.2011.41.0308
Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., et al. (2020). Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J. Immunother. Cancer 8 (2), e001361. doi:10.1136/jitc-2020-001361
Crokart, N., Radermacher, K., Jordan, B. F., Baudelet, C., Cron, G. O., Grégoire, V., et al. (2005). Tumor radiosensitization by antiinflammatory drugs: Evidence for a new mechanism involving the oxygen effect. Cancer Res. 65 (17), 7911–7916. doi:10.1158/0008-5472.Can-05-1288
Crusz, S. M., and Balkwill, F. R. (2015). Inflammation and cancer: Advances and new agents. Nat. Rev. Clin. Oncol. 12 (10), 584–596. doi:10.1038/nrclinonc.2015.105
Cui, H. Y., Wang, S. J., Song, F., Cheng, X., Nan, G., Zhao, Y., et al. (2021). CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Signal Transduct. Target. Ther. 6 (1), 268. doi:10.1038/s41392-021-00677-2
Daikoku, T., Wang, D., Tranguch, S., Morrow, J. D., Orsulic, S., DuBois, R. N., et al. (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65 (9), 3735–3744. doi:10.1158/0008-5472.Can-04-3814
Din, F. V., Valanciute, A., Houde, V. P., Zibrova, D., Green, K. A., Sakamoto, K., et al. (2012). Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142 (7), 15041504–15041515. doi:10.1053/j.gastro.2012.02.050
Domingo, E., Church, D. N., Sieber, O., Ramamoorthy, R., Yanagisawa, Y., Johnstone, E., et al. (2013). Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31 (34), 4297–4305. doi:10.1200/jco.2013.50.0322
Dong, Z., Huang, C., Brown, R. E., and Ma, W. Y. (1997). Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J. Biol. Chem. 272 (15), 9962–9970. doi:10.1074/jbc.272.15.9962
Edelman, M. J., Watson, D., Wang, X., Morrison, C., Kratzke, R. A., Jewell, S., et al. (2008). Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-cancer and leukemia group B trial 30203. J. Clin. Oncol. 26 (6), 848–855. doi:10.1200/jco.2007.13.8081
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., and Flavell, R. A. (2013). Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13 (11), 759–771. doi:10.1038/nrc3611
Elmets, C. A., Viner, J. L., Pentland, A. P., Cantrell, W., Lin, H. Y., Bailey, H., et al. (2010). Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial. J. Natl. Cancer Inst. 102 (24), 1835–1844. doi:10.1093/jnci/djq442
Fang, M., Li, Y., Huang, K., Qi, S., Zhang, J., Zgodzinski, W., et al. (2017). IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Res. 77 (10), 2735–2745. doi:10.1158/0008-5472.Can-16-1602
Feng, R., Anderson, G., Xiao, G., Elliott, G., Leoni, L., Mapara, M. Y., et al. (2007). SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 109 (5), 2130–2138. doi:10.1182/blood-2006-07-027458
Fraser, D. M., Sullivan, F. M., Thompson, A. M., and McCowan, C. (2014). Aspirin use and survival after the diagnosis of breast cancer: A population-based cohort study. Br. J. Cancer 111 (3), 623–627. doi:10.1038/bjc.2014.264
Frouws, M. A., Bastiaannet, E., Langley, R. E., Chia, W. K., van Herk-Sukel, M. P., Lemmens, V. E., et al. (2017). Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. Br. J. Cancer 116 (3), 405–413. doi:10.1038/bjc.2016.425
Fujiwara, N., Singal, A. G., and Hoshida, Y. (2019). Dose and duration of aspirin use to reduce incident hepatocellular carcinoma. Hepatology 70 (6), 2216–2217. doi:10.1002/hep.30813
Fullerton, J. N., and Gilroy, D. W. (2016). Resolution of inflammation: A new therapeutic frontier. Nat. Rev. Drug Discov. 15 (8), 551–567. doi:10.1038/nrd.2016.39
Funk, C. D. (2001). Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294 (5548), 1871–1875. doi:10.1126/science.294.5548.1871
Gadgeel, S. M., Ruckdeschel, J. C., Heath, E. I., Heilbrun, L. K., Venkatramanamoorthy, R., and Wozniak, A. (2007). Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2 (4), 299–305. doi:10.1097/01.Jto.0000263712.61697.69
Gallouet, A. S., Travert, M., Bresson-Bepoldin, L., Guilloton, F., Pangault, C., Caulet-Maugendre, S., et al. (2014). COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Clin. Cancer Res. 20 (10), 2663–2673. doi:10.1158/1078-0432.Ccr-13-2305
Gholamian Dehkordi, N., Mirzaei, S. A., and Elahian, F. (2021). Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness. Inflammopharmacology 29 (1), 49–74. doi:10.1007/s10787-020-00765-9
Giampieri, R., Restivo, A., Pusceddu, V., Del Prete, M., Maccaroni, E., Bittoni, A., et al. (2017). The role of aspirin as antitumoral agent for heavily pretreated patients with metastatic colorectal cancer receiving capecitabine monotherapy. Clin. Colorectal Cancer 16 (1), 38–43. doi:10.1016/j.clcc.2016.07.011
Greten, F. R., and Grivennikov, S. I. (2019). Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 51 (1), 27–41. doi:10.1016/j.immuni.2019.06.025
Gridelli, C., Gallo, C., Ceribelli, A., Gebbia, V., Gamucci, T., Ciardiello, F., et al. (2007). Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet. Oncol. 8 (6), 500–512. doi:10.1016/s1470-2045(07)70146-8
Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140 (6), 883–899. doi:10.1016/j.cell.2010.01.025
Hamada, T., Cao, Y., Qian, Z. R., Masugi, Y., Nowak, J. A., Yang, J., et al. (2017). Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J. Clin. Oncol. 35 (16), 1836–1844. doi:10.1200/jco.2016.70.7547
Han, R., Hao, S., Lu, C., Zhang, C., Lin, C., Li, L., et al. (2020). Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction. Mol. Oncol. 14 (6), 1152–1169. doi:10.1002/1878-0261.12682
Hashemi Goradel, N., Najafi, M., Salehi, E., Farhood, B., and Mortezaee, K. (2019). Cyclooxygenase-2 in cancer: A review. J. Cell. Physiol. 234 (5), 5683–5699. doi:10.1002/jcp.27411
Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. J., et al. (2012). The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336 (6083), 918–922. doi:10.1126/science.1215327
He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. (1999). PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99 (3), 335–345. doi:10.1016/s0092-8674(00)81664-5
Holmes, C. E., Huang, J. C., Pace, T. R., Howard, A. B., and Muss, H. B. (2008). Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin. Cancer Res. 14 (10), 3070–3076. doi:10.1158/1078-0432.Ccr-07-4640
Hou, J., Karin, M., and Sun, B. (2021). Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat. Rev. Clin. Oncol. 18 (5), 261–279. doi:10.1038/s41571-020-00459-9
Hurwitz, L. M., Townsend, M. K., Jordan, S. J., Patel, A. V., Teras, L. R., Lacey, J. V., et al. (2022). Modification of the association between frequent aspirin use and ovarian cancer risk: A meta-analysis using individual-level data from two ovarian cancer consortia. J. Clin. Oncol., Jco2101900. doi:10.1200/jco.21.01900
Jacobs, E. J., Newton, C. C., Stevens, V. L., Campbell, P. T., Freedland, S. J., and Gapstur, S. M. (2014). Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J. Clin. Oncol. 32 (33), 3716–3722. doi:10.1200/jco.2013.54.8875
Jiang, J., Qiu, J., Li, Q., and Shi, Z. (2017). Prostaglandin E2 signaling: Alternative target for glioblastoma? Trends Cancer 3 (2), 75–78. doi:10.1016/j.trecan.2016.12.002
Jiang, M. J., Chen, Y. Y., Dai, J. J., Gu, D. N., Mei, Z., Liu, F. R., et al. (2020). Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer. Mol. Cancer 19 (1), 68. doi:10.1186/s12943-020-01178-6
Johnson, A. J., Hsu, A. L., Lin, H. P., Song, X., and Chen, C. S. (2002). The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: A plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 366 (3), 831–837. doi:10.1042/bj20020279
Kato, T., Fujino, H., Oyama, S., Kawashima, T., and Murayama, T. (2011). Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: A novel cyclooxygenase-inhibition-independent effect. Biochem. Pharmacol. 82 (11), 1781–1791. doi:10.1016/j.bcp.2011.07.096
Kern, M. A., Haugg, A. M., Koch, A. F., Schilling, T., Breuhahn, K., Walczak, H., et al. (2006). Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 66 (14), 7059–7066. doi:10.1158/0008-5472.Can-06-0325
Khalaf, N., Yuan, C., Hamada, T., Cao, Y., Babic, A., Morales-Oyarvide, V., et al. (2018). Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies. Gastroenterology 154 (5), 1380–1390. e1385. doi:10.1053/j.gastro.2017.12.001
Kolluri, S. K., Corr, M., James, S. Y., Bernasconi, M., Lu, D., Liu, W., et al. (2005). The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc. Natl. Acad. Sci. U. S. A. 102 (7), 2525–2530. doi:10.1073/pnas.0409721102
Kulp, S. K., Yang, Y. T., Hung, C. C., Chen, K. F., Lai, J. P., Tseng, P. H., et al. (2004). 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64 (4), 1444–1451. doi:10.1158/0008-5472.can-03-2396
Lee, E. J., Kim, S. J., Hahn, Y. I., Yoon, H. J., Han, B., Kim, K., et al. (2019). 15-Keto prostaglandin E(2) suppresses STAT3 signaling and inhibits breast cancer cell growth and progression. Redox Biol. 23, 101175. doi:10.1016/j.redox.2019.101175
Li, H. J., Reinhardt, F., Herschman, H. R., and Weinberg, R. A. (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2 (9), 840–855. doi:10.1158/2159-8290.Cd-12-0101
Li, H., Zhu, F., Chen, H., Cheng, K. W., Zykova, T., Oi, N., et al. (2014). 6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1. Cancer Res. 74 (1), 243–252. doi:10.1158/0008-5472.Can-13-2245
Li, P., Wu, H., Zhang, H., Shi, Y., Xu, J., Ye, Y., et al. (2015). Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis. Gut 64 (9), 1419–1425. doi:10.1136/gutjnl-2014-308260
Liao, D., Zhong, L., Duan, T., Zhang, R. H., Wang, X., Wang, G., et al. (2015). Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-κB pathway. Clin. Cancer Res. 21 (23), 5349–5359. doi:10.1158/1078-0432.Ccr-15-0198
Liao, S. F., Koshiol, J., Huang, Y. H., Jackson, S. S., Huang, Y. H., Chan, C., et al. (2021). Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort. Hepatology 74 (4), 1994–2006. doi:10.1002/hep.31879
Liou, J. Y., Ghelani, D., Yeh, S., and Wu, K. K. (2007). Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 67 (7), 3185–3191. doi:10.1158/0008-5472.Can-06-3431
Liu, G., Ma, W. Y., Bode, A. M., Zhang, Y., and Dong, Z. (2003). NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. J. Biol. Chem. 278 (4), 2124–2130. doi:10.1074/jbc.M202443200
Liu, L., Ge, D., Ma, L., Mei, J., Liu, S., Zhang, Q., et al. (2012). Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J. Thorac. Oncol. 7 (7), 1091–1100. doi:10.1097/JTO.0b013e3182542752
Liu, X., Hong, L., Nilsson, M., Hubert, S. M., Wu, S., Rinsurongkawong, W., et al. (2020). Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 149, 33–40. doi:10.1016/j.lungcan.2020.08.023
Loomans-Kropp, H. A., Pinsky, P., and Umar, A. (2021). Evaluation of aspirin use with cancer incidence and survival among older adults in the prostate, lung, colorectal, and ovarian cancer screening trial. JAMA Netw. Open 4 (1), e2032072. doi:10.1001/jamanetworkopen.2020.32072
Lotrionte, M., Biasucci, L. M., Peruzzi, M., Frati, G., Giordano, A., and Biondi-Zoccai, G. (2016). Which aspirin dose and preparation is best for the long-term prevention of cardiovascular disease and cancer? Evidence from a systematic review and network meta-analysis. Prog. Cardiovasc. Dis. 58 (5), 495–504. doi:10.1016/j.pcad.2016.02.001
Lu, L., Zhang, Q., Wu, K., Chen, X., Zheng, Y., Zhu, C., et al. (2015). Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-κB signal cascade. Cancer Lett. 356 (2), 470–478. doi:10.1016/j.canlet.2014.09.027
Lucotti, S., Cerutti, C., Soyer, M., Gil-Bernabé, A. M., Gomes, A. L., Allen, P. D., et al. (2019). Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J. Clin. Invest. 129 (5), 1845–1862. doi:10.1172/jci121985
Lynch, P. M., Ayers, G. D., Hawk, E., Richmond, E., Eagle, C., Woloj, M., et al. (2010). The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am. J. Gastroenterol. 105 (6), 1437–1443. doi:10.1038/ajg.2009.758
Ma, L., Gonzalez-Junca, A., Zheng, Y., Ouyang, H., Illa-Bochaca, I., Horst, K. C., et al. (2021a). Inflammation mediates the development of aggressive breast cancer following radiotherapy. Clin. Cancer Res. 27 (6), 1778–1791. doi:10.1158/1078-0432.Ccr-20-3215
Ma, S., Guo, C., Sun, C., Han, T., Zhang, H., Qu, G., et al. (2021b). Aspirin use and risk of breast cancer: A meta-analysis of observational studies from 1989 to 2019. Clin. Breast Cancer 21 (6), 552–565. doi:10.1016/j.clbc.2021.02.005
Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., et al. (2016). Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J. Crohns Colitis 10 (4), 395–401. doi:10.1093/ecco-jcc/jjv227
Mc Menamin Ú, C., Cardwell, C. R., Hughes, C. M., and Murray, L. M. (2015). Low-dose aspirin and survival from lung cancer: A population-based cohort study. BMC Cancer 15, 911. doi:10.1186/s12885-015-1910-9
McNeil, J. J., Gibbs, P., Orchard, S. G., Lockery, J. E., Bernstein, W. B., Cao, Y., et al. (2021). Effect of aspirin on cancer incidence and mortality in older adults. J. Natl. Cancer Inst. 113 (3), 258–265. doi:10.1093/jnci/djaa114
McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., et al. (2018). Effect of aspirin on all-cause mortality in the healthy elderly. N. Engl. J. Med. 379 (16), 1519–1528. doi:10.1056/NEJMoa1803955
Meyerhardt, J. A., Shi, Q., Fuchs, C. S., Meyer, J., Niedzwiecki, D., Zemla, T., et al. (2021). Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: The CALGB/SWOG 80702 (alliance) randomized clinical trial. Jama 325 (13), 1277–1286. doi:10.1001/jama.2021.2454
Moon, C. M., Kwon, J. H., Kim, J. S., Oh, S. H., Jin Lee, K., Park, J. J., et al. (2014). Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int. J. Cancer 134 (3), 519–529. doi:10.1002/ijc.28381
Nan, H., Hutter, C. M., Lin, Y., Jacobs, E. J., Ulrich, C. M., White, E., et al. (2015). Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. Jama 313 (11), 1133–1142. doi:10.1001/jama.2015.1815
Oh, S. W., Myung, S. K., Park, J. Y., Lee, C. M., and Kwon, H. T. (2011). Aspirin use and risk for lung cancer: A meta-analysis. Ann. Oncol. 22 (11), 2456–2465. doi:10.1093/annonc/mdq779
Pennarun, B., Kleibeuker, J. H., Boersma-van Ek, W., Kruyt, F. A., Hollema, H., de Vries, E. G., et al. (2013). Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. J. Pathol. 229 (3), 410–421. doi:10.1002/path.4138
Pi, C., Jing, P., Li, B., Feng, Y., Xu, L., Xie, K., et al. (2022). Reversing PD-1 resistance in B16F10 cells and recovering tumour immunity using a COX2 inhibitor. Cancers (Basel) 14 (17), 4134. doi:10.3390/cancers14174134
Pradono, P., Tazawa, R., Maemondo, M., Tanaka, M., Usui, K., Saijo, Y., et al. (2002). Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 62 (1), 63–66.
Rader, J. S., Sill, M. W., Beumer, J. H., Lankes, H. A., Benbrook, D. M., Garcia, F., et al. (2017). A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol. 145 (2), 291–297. doi:10.1016/j.ygyno.2017.02.040
Ramírez, J., House, L. K., Karrison, T. G., Janisch, L. A., Turcich, M., Salgia, R., et al. (2019). Prolonged pharmacokinetic interaction between capecitabine and a CYP2C9 substrate, celecoxib. J. Clin. Pharmacol. 59 (12), 1632–1640. doi:10.1002/jcph.1476
Reckamp, K. L., Krysan, K., Morrow, J. D., Milne, G. L., Newman, R. A., Tucker, C., et al. (2006). A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin. Cancer Res. 12 (11), 3381–3388. doi:10.1158/1078-0432.Ccr-06-0112
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., et al. (2019). Pharmacogenomics. Lancet 394 (10197), 521–532. doi:10.1016/s0140-6736(19)31276-0
Saha, S., Mukherjee, S., Khan, P., Kajal, K., Mazumdar, M., Manna, A., et al. (2016). Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an nf?b-IL6 signaling Axis responsible for the generation of cancer stem cells. Cancer Res. 76 (7), 2000–2012. doi:10.1158/0008-5472.Can-15-1360
Salvado, M. D., Di Gennaro, A., Lindbom, L., Agerberth, B., and Haeggström, J. Z. (2013). Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Arterioscler. Thromb. Vasc. Biol. 33 (8), 1965–1972. doi:10.1161/atvbaha.113.301851
Samowitz, W. S., Wolff, R. K., Curtin, K., Sweeney, C., Ma, K. N., Andersen, K., et al. (2006). Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin. Gastroenterol. Hepatol. 4 (7), 894–901. doi:10.1016/j.cgh.2006.04.021
Saxena, P., Sharma, P. K., and Purohit, P. (2020). A journey of celecoxib from pain to cancer. Prostagl. Other Lipid Mediat. 147, 106379. doi:10.1016/j.prostaglandins.2019.106379
Scherer, D., Koepl, L. M., Poole, E. M., Balavarca, Y., Xiao, L., Baron, J. A., et al. (2014). Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry. Genes Chromosom. Cancer 53 (7), 568–578. doi:10.1002/gcc.22167
Schjerning, A. M., McGettigan, P., and Gislason, G. (2020). Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat. Rev. Cardiol. 17 (9), 574–584. doi:10.1038/s41569-020-0366-z
Seufert, B. L., Poole, E. M., Whitton, J., Xiao, L., Makar, K. W., Campbell, P. T., et al. (2013). IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis 34 (1), 79–85. doi:10.1093/carcin/bgs296
Shishodia, S., and Aggarwal, B. B. (2004). Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: Correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res. 64 (14), 5004–5012. doi:10.1158/0008-5472.Can-04-0206
Simon, T. G., Duberg, A. S., Aleman, S., Chung, R. T., Chan, A. T., and Ludvigsson, J. F. (2020). Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382 (11), 1018–1028. doi:10.1056/NEJMoa1912035
Slattery, M. L., Lundgreen, A., and Wolff, R. K. (2014). VEGFA, FLT1, KDR and colorectal cancer: Assessment of disease risk, tumor molecular phenotype, and survival. Mol. Carcinog. 53 (1), E140–E150. doi:10.1002/mc.22058
Strasser-Weippl, K., Higgins, M. J., Chapman, J. W., Ingle, J. N., Sledge, G. W., Budd, G. T., et al. (2018). Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor-treated patients: Cctg MA.27. J. Natl. Cancer Inst. 110 (9), 1003–1008. doi:10.1093/jnci/djy017
Sun, D., Liu, H., Dai, X., Zheng, X., Yan, J., Wei, R., et al. (2017). Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Lett. 406, 105–115. doi:10.1016/j.canlet.2017.06.029
Sun, K., Yu, J., Hu, J., Chen, J., Song, J., Chen, Z., et al. (2022). Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment. Acta Biomater. 148, 230–243. doi:10.1016/j.actbio.2022.06.026
Sun, Y., Dai, H., Chen, S., Zhang, Y., Wu, T., Cao, X., et al. (2018). Disruption of chromosomal architecture of cox2 locus sensitizes lung cancer cells to radiotherapy. Mol. Ther. 26 (10), 2456–2465. doi:10.1016/j.ymthe.2018.08.002
Sweeney, C. J., Takimoto, C. H., Latz, J. E., Baker, S. D., Murry, D. J., Krull, J. H., et al. (2006). Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin. Cancer Res. 12 (2), 536–542. doi:10.1158/1078-0432.Ccr-05-1834
Takada, Y., Bhardwaj, A., Potdar, P., and Aggarwal, B. B. (2004). Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23 (57), 9247–9258. doi:10.1038/sj.onc.1208169
Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., et al. (2020). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin. Pharmacol. Ther. 108 (2), 191–200. doi:10.1002/cpt.1830
Thompson, P. A., Huang, C., Yang, J., Wertheim, B. C., Roe, D., Zhang, X., et al. (2021). Sulindac, a nonselective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors. Clin. Cancer Res. 27 (20), 5660–5668. doi:10.1158/1078-0432.Ccr-21-0732
Tinsley, H. N., Gary, B. D., Keeton, A. B., Zhang, W., Abadi, A. H., Reynolds, R. C., et al. (2009). Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther. 8 (12), 3331–3340. doi:10.1158/1535-7163.Mct-09-0758
Tinsley, H. N., Gary, B. D., Thaiparambil, J., Li, N., Lu, W., Li, Y., et al. (2010). Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res. 3 (10), 1303–1313. doi:10.1158/1940-6207.Capr-10-0030
Ullman, T. A., and Itzkowitz, S. H. (2011). Intestinal inflammation and cancer. Gastroenterology 140 (6), 1807–1816. doi:10.1053/j.gastro.2011.01.057
Ulrich, C. M., Bigler, J., and Potter, J. D. (2006). Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat. Rev. Cancer 6 (2), 130–140. doi:10.1038/nrc1801
Walter, R. B., Milano, F., Brasky, T. M., and White, E. (2011). Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: Results from the prospective vitamins and lifestyle (VITAL) study. J. Clin. Oncol. 29 (17), 2424–2431. doi:10.1200/jco.2011.34.6346
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., et al. (2021a). Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets. Signal Transduct. Target. Ther. 6 (1), 94. doi:10.1038/s41392-020-00443-w
Wang, D., Cabalag, C. S., Clemons, N. J., and DuBois, R. N. (2021b). Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology 161 (6), 1813–1829. doi:10.1053/j.gastro.2021.09.059
Wang, D., and Dubois, R. N. (2010). Eicosanoids and cancer. Nat. Rev. Cancer 10 (3), 181–193. doi:10.1038/nrc2809
Wang, D., and Dubois, R. N. (2006). Prostaglandins and cancer. Gut 55 (1), 115–122. doi:10.1136/gut.2004.047100
Wang, D., Fu, L., Sun, H., Guo, L., and DuBois, R. N. (2015). Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology 149 (7), 1884e1884–1895. doi:10.1053/j.gastro.2015.07.064
Wang, L., Zhang, R., Yu, L., Xiao, J., Zhou, X., Li, X., et al. (2021c). Aspirin use and common cancer risk: A meta-analysis of cohort studies and randomized controlled trials. Front. Oncol. 11, 690219. doi:10.3389/fonc.2021.690219
Wang, T., McCullough, L. E., White, A. J., Bradshaw, P. T., Xu, X., Cho, Y. H., et al. (2019). Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study. Cancer 125 (21), 3836–3844. doi:10.1002/cncr.32364
Wang, Y., Wang, M., Liu, C., Wang, W., Shi, J., and Dang, S. (2022). Aspirin use and the risk of hepatocellular carcinoma: A meta-analysis. J. Clin. Gastroenterol. 56 (7), e293–e302. doi:10.1097/mcg.0000000000001693
Wang, Y., Zhao, J., Chen, X., Zhang, F., and Li, X. (2020). Aspirin use and endometrial cancer risk: A meta-analysis and systematic review. Ann. Transl. Med. 8 (7), 461. doi:10.21037/atm.2020.03.125
Wei, D., Wang, L., He, Y., Xiong, H. Q., Abbruzzese, J. L., and Xie, K. (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64 (6), 2030–2038. doi:10.1158/0008-5472.can-03-1945
White, M. C., Johnson, G. G., Zhang, W., Hobrath, J. V., Piazza, G. A., and Grimaldi, M. (2013). Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: Relevant similarities to and important differences from celecoxib. J. Neurosci. Res. 91 (3), 393–406. doi:10.1002/jnr.23169
Wick, M., Hurteau, G., Dessev, C., Chan, D., Geraci, M. W., Winn, R. A., et al. (2002). Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 62 (5), 1207–1214. doi:10.1124/mol.62.5.1207
Wong, C. C., Kang, W., Xu, J., Qian, Y., Luk, S. T. Y., Chen, H., et al. (2019). Prostaglandin E(2) induces DNA hypermethylation in gastric cancer in vitro and in vivo. Theranostics 9 (21), 6256–6268. doi:10.7150/thno.35766
Xia, D., Wang, D., Kim, S. H., Katoh, H., and DuBois, R. N. (2012). Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med. 18 (2), 224–226. doi:10.1038/nm.2608
Xu, L., Stevens, J., Hilton, M. B., Seaman, S., Conrads, T. P., Veenstra, T. D., et al. (2014). COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl. Med. 6 (242), 242ra84. doi:10.1126/scitranslmed.3008455
Yamazaki, H., Shimizu, M., Otani, T., Mizugaki, A., Mure, K., Suzuki, S., et al. (2021). Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: Insights into future personalized treatments. J. Pharm. Health Care Sci. 7 (1), 26. doi:10.1186/s40780-021-00209-8
Yanaoka, K., Oka, M., Yoshimura, N., Deguchi, H., Mukoubayashi, C., Enomoto, S., et al. (2010). Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int. J. Cancer 126 (6), 1467–1473. doi:10.1002/ijc.24862
Yang, L., Francois, F., and Pei, Z. (2012). Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin. Cancer Res. 18 (8), 2138–2144. doi:10.1158/1078-0432.Ccr-11-0934
Zhang, X., Du, R., Luo, N., Xiang, R., and Shen, W. (2020). Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner. Stem Cell Res. Ther. 11 (1), 370. doi:10.1186/s13287-020-01884-4
Zhang, Y., Chen, H., Chen, S., Li, Z., Chen, J., and Li, W. (2021). The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Oncoimmunology 10 (1), 1957605. doi:10.1080/2162402x.2021.1957605
Zhang, Y., and Daaka, Y. (2011). PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood 118 (19), 5355–5364. doi:10.1182/blood-2011-04-350587
Zhang, Y., Kumar, P., Adashek, J. J., Skelton, W. P. t., Li, J., Vosoughi, A., et al. (2022). Adding cyclooxygenase inhibitors to immune checkpoint inhibitors did not improve outcomes in metastatic renal cell carcinoma. Cells 11 (16), 2505. doi:10.3390/cells11162505
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., et al. (2021). Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct. Target. Ther. 6 (1), 263. doi:10.1038/s41392-021-00658-5
Zheng, S. L., and Roddick, A. J. (2019). Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis. Jama 321 (3), 277–287. doi:10.1001/jama.2018.20578
Zhou, H., Liu, W., Su, Y., Wei, Z., Liu, J., Kolluri, S. K., et al. (2010). NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 17 (6), 560–573. doi:10.1016/j.ccr.2010.04.023
Keywords: cancer, inflammation, cyclooxygenase, non-steroidal anti-inflammatory drugs, pharmacogenomics
Citation: Lai H, Liu Y, Wu J, Cai J, Jie H, Xu Y and Deng S (2022) Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics. Front. Pharmacol. 13:1078766. doi: 10.3389/fphar.2022.1078766
Received: 24 October 2022; Accepted: 25 November 2022;
Published: 05 December 2022.
Edited by:
Chen Lin, Mayo Clinic, United StatesReviewed by:
Federica Finetti, University of Siena, ItalyGao Zhang, The University of Hong Kong, Hong Kong SAR, China
Copyright © 2022 Lai, Liu, Wu, Cai, Jie, Xu and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuyang Xu, michael19xyy@aliyun.com; Senyi Deng, senyi_deng@scu.edu.cn
†These authors have contributed equally to this work